PremiumCompany AnnouncementsArgenica Therapeutics Announces Director Resignation Argenica Therapeutics Reports Reduced Losses Amid Increased R&D Costs Argenica’s ARG-007 Demonstrates Key Neuroprotective Effects in TBI Study PremiumCompany AnnouncementsArgenica’s Clinical Trial Progress and Financial Health Argenica Therapeutics Gains FDA Designations for ARG-006 Argenica Therapeutics Schedules 2024 AGM PremiumCompany AnnouncementsArgenica’s Stroke Trial Advances Unchanged Argenica Therapeutics Emphasizes Strong Governance Argenica Therapeutics Strengthens Assets Despite Losses